Mar 03,2023

Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

Validated questionnaires are used to assess asthma control over the past 1–4 weeks from reporting. However, they do not adequately capture asthma control in patients with fluctuating symptoms. Using the Mobile Airways Sentinel Network for airway diseases (MASK-air) app, this study developed and validated an electronic daily asthma control score (e-DASTHMA). e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation.

CLINICAL STUDY

#mobile app

#rpm

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

Fitterfly presents outcomes from Digital Therapeutics Platform at 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), Germany

Fitterfly's first presentation focused on how their Digital Therapeutics solutions were able to benefit the participants through use of CGM-led behavior change, and personalized lifestyle changes during the 90-day program. Study data included 145 patients who were put on a CGM device for 14 days and then received personalised coaching based on their glycemic responses for next 11 weeks. The study showed 10% improvement in Time in Range (from 66% to 72%) within 14 days and 1% reduction in HbA1c from a baseline of 8.1% in 3 months. This was also accompanied by an average of 2.3 kg of weight loss. UKPDS studies have shown that 1% reduction in HbA1c has significant benefits in terms of 14% reduction in all cause mortality, 30% reduction in retinopathy, kidney failure and strokes. Second study showed predictive insights for the need for CGM calibration and improved usage. This can be a transformational change as it will reduce the need for conventional finger prick tests for diabetes measurement.

CLINICAL STUDY

#connected device

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 06,2023

Fitterfly presents outcomes from Digital Therapeutics Platform at 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), Germany

Fitterfly's first presentation focused on how their Digital Therapeutics solutions were able to benefit the participants through use of CGM-led behavior change, and personalized lifestyle changes during the 90-day program. Study data included 145 patients who were put on a CGM device for 14 days and then received personalised coaching based on their glycemic responses for next 11 weeks. The study showed 10% improvement in Time in Range (from 66% to 72%) within 14 days and 1% reduction in HbA1c from a baseline of 8.1% in 3 months. This was also accompanied by an average of 2.3 kg of weight loss.

CLINICAL STUDY

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 15,2023

Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer

Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk stratification among men with clinically high-risk prostate cancer. The data, from a pre-specified analysis of three phase 3 trials, represent the first validation of any gene-expression biomarker on pre-treatment biopsy samples from prospective randomized trials, and suggest the Decipher test provides clinically useful prognostic information to help personalize shared treatment decision-making.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 15,2023

Cancer Symptom Algorithm Presented in JNCCN Can Aid Doctors in Predicting Patients at Risk for Unplanned Emergency Visits

New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs. The researchers used the Edmonton Symptom Assessment System-Revised (ESASr) as a measurement tool for the most-common symptoms experienced by people with cancer. After classifying each patient's symptom complexity based on the number and severity of symptoms reported, the researchers correlated the symptom complexity with the odds of having an ED visit within a week.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 27,2023 TOP STORY

New Research from Dario Demonstrates Improved Clinical Outcomes in Two New Studies at the Advanced Technologies and Treatments for Diabetes 2023 Conference

DarioHealth Corp. announced today two new clinical studies presented at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2023, which was held February 22-25 in Berlin. One of the studies demonstrated improved clinical outcomes in users with Type 2 diabetes and provided further analysis to understand the mediating effects of live human coaching and digital interventions across the Dario user journey. The second study demonstrated Dario's ability to reduce hypoglycemic events in older adults with a digital chronic condition management solution.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 21,2023

Lark Health’s Artificial Intelligence (AI) Heart Health Program Significantly Improves Cardiac Self-Efficacy

The pilot study, “Cardiac Self-Efficacy Improvement in a Digital Health Pilot Program for Heart Health” found that, on average, study participants increased their Cardiac Self-Efficacy (CSE) score by 12.93 percent, the first digital care solution to show CSE improvement. The CSE study results will be presented at The Society of Behavioral Medicine's 44th Annual Meeting & Scientific Sessions in Phoenix, AZ, from April 26–29, 2023.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 27,2023

New Research from Dario Demonstrates Improved Clinical Outcomes in Two New Studies at the Advanced Technologies and Treatments for Diabetes 2023 Conference

DarioHealth Corp. announced today two new clinical studies presented at the 16th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2023, which was held February 22-25 in Berlin. One of the studies demonstrated improved clinical outcomes in users with Type 2 diabetes and provided further analysis to understand the mediating effects of live human coaching and digital interventions across the Dario user journey. The second study demonstrated Dario's ability to reduce hypoglycemic events in older adults with a digital chronic condition management solution.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 22,2023

MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it will present an oral presentation describing meal challenge results at the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD) in Berlin February 22-25. The data showed that subjects utilizing inhaled Technosphere Insulin (TI) lowered peak glucose levels 30 minutes faster (200 mg/dl at 60 minutes) than subjects utilizing a rapid-acting analogue (RAA) with an Automated Insulin Delivery (AID) system (264 mg/dl at 90 minutes). Subjects utilizing TI also experienced a significantly lower mean PPG from 45 to 120 minutes post-meal.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 24,2023 TOP STORY

MiniMed™ 780G system demonstrates superiority over multiple daily injections with CGM for type 1 diabetes management at one-year in ADAPT study

Medtronic today announced one-year data from the ADAPT study (n=82), the first multi-national randomized controlled study comparing the performance of the MiniMed™ 780G advanced hybrid closed loop system1 (AHCL) against multiple daily injections (MDI) of insulin with an intermittently scanned CGM (isCGM). The study was done in adults (18 years of age and older) not meeting glycemic targets. The initial 6-month results, published in The Lancet Diabetes & Endocrinology, showed AHCL system users experienced a 27.6% absolute increase in Time in Range (TIR) and 1.4% reduction in HbA1C compared to those on MDI + isCGM without increased time in hypoglycemia. These latest results were presented today at the 2023 Advanced Technologies & Treatments for Diabetes (ATTD) Conference in Berlin.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY